Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Conditions
- Clear Cell Sarcoma of the Kidney
- Recurrent Renal Cell Carcinoma
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer
Interventions
- DRUG: Dalteparin
- OTHER: Pharmacological Study
- DRUG: Sunitinib Malate
Sponsor
Roswell Park Cancer Institute
Collaborators